Literature DB >> 3182087

Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin.

M Mayer1, C Tophof, W Opferkuch.   

Abstract

Twenty-four patients undergoing gall bladder surgery and placement of a Kehr T-tube were examined for imipenem pharmacokinetics in plasma and bile fluid following an intravenous short-term infusion (20 min) of 500 mg respectively 1000 mg each of imipenem and cilastatin. In group I (500 mg; 12 patients) a mean peak concentration in bile fluid of 10.5 mg/l (range 1.5 to 16.7 mg/l) was reached just after 10 min. 60 min after the end of infusion the imipenem concentration was between 8 and 9 mg/l. In group I the half-life of imipenem in bile was 0.84 h. In group II (1000 mg; 12 patients) the mean peak level in bile fluid was 1&.5 mg/l (range 3.5 to 51.3 mg/l). The half-life in bile was 1.24 h in this group. The data indicated that 4 h after the administration of either 1000 mg or 500 mg, imipenem serum and bile concentrations were markedly above the MIC values for pathogens expected to be found in infections of the biliary tract.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182087     DOI: 10.1007/bf01650757

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

Review 1.  The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.

Authors:  H C Neu
Journal:  Annu Rev Pharmacol Toxicol       Date:  1982       Impact factor: 13.820

2.  The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species.

Authors:  M H RIchmond
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

3.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

4.  In vitro activity of thienamycin.

Authors:  P M Shah
Journal:  Methods Find Exp Clin Pharmacol       Date:  1981 Nov-Dec

5.  Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.

Authors:  S R Norrby; J D Rogers; F Ferber; K H Jones; A G Zacchei; L L Weidner; J L Demetriades; D A Gravallese; J Y Hsieh
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.

Authors:  I Braveny; K Machka; R Elsser
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

8.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.

Authors:  J E Brown; V E Del Bene; C D Collins
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

10.  [Antibacterial activity of N-formimidoyl-thienamycin in comparison with other beta-lactam antibiotics against clinical problem strains (author's transl)].

Authors:  H Grimm
Journal:  Arzneimittelforschung       Date:  1982
View more
  1 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.